Biomea Fusion (NASDAQ: BMEA), a clinical-stage diabetes and obesity company, has commenced an underwritten public offering of its common stock and pre-funded warrants. The offering is subject to market conditions and other factors.

Offering Structure and Terms

The proposed offering includes shares of common stock and, in lieu of common stock for certain investors, pre-funded warrants to purchase shares. Biomea intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the total number of securities in the proposed offering. All shares and warrants being sold are issued directly by Biomea.

Konik Capital Partners, LLC, a division of T.R. Winston & Company, is acting as the sole underwriter for the transaction.

Regulatory Framework

The offering is conducted pursuant to an effective shelf registration statement on Form S-3 (File No. 333-289262). This statement was filed with the U.S. Securities and Exchange Commission (SEC) on August 5, 2025, and declared effective on August 15, 2025. A preliminary prospectus supplement and accompanying prospectus describing the final terms will be filed with the SEC.

Corporate Context

Biomea Fusion focuses on developing oral small molecule therapies, specifically icovamenib and BMF-650, targeting metabolic disorders such as diabetes and obesity. The company states its mission is to deliver transformative treatments for patients living with these conditions.

The press release notes that the proposed offering is subject to completion based on market conditions, with no assurance regarding the timing, size, or terms of the final deal. This announcement does not constitute an offer to sell or a solicitation of an offer to buy securities in jurisdictions where such actions would be unlawful prior to registration.

Biomea Fusion announced that topline data from the Phase 1 obesity trial of its experimental drug BMF-650 is now expected in October, a delay from the previously anticipated third quarter timeline.

The company disclosed the revised schedule in a filing with the U.S. Securities and Exchange Commission on September 22, 2026. The update pertains specifically to the initial safety and tolerability results for the oral small molecule designed for metabolic indications.

Trial timeline adjustment

The shift in timing moves the release of key clinical findings from Q3 to Q4 of the calendar year. Biomea Fusion did not provide specific reasons for the delay in the available text, nor did it alter the scope or endpoints of the ongoing study.

This adjustment impacts the near-term catalyst schedule for investors monitoring the asset's progression through early-stage clinical development.